Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Files Lasofoxifene NDA For Treatment Of Osteoporsis

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Pfizer could be just one step behind Wyeth in getting a new selective estrogen receptor modulator approved and on the market for the treatment of osteoporosis in postmenopausal women. The drug maker has submitted an NDA for Fablyn (lasofoxifene, formerly Oporia) in that indication, development partner Ligand announced Jan. 15.

You may also be interested in...



Pfizer/Ligand Lasofoxifene Is First "Next-Generation" SERM Filed At FDA

Pfizer/Ligand’s lasofoxifene could be the first approved "next-generation" selective estrogen receptor modulator for osteoporosis.

Sandoz Optimistic On Biosimilars As It Reprioritizes US Portfolio

Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.

FDA Requests Belviq Be Pulled From The US Market Due To Cancer Risk

The agency requested the weight loss pill be voluntarily recalled by Eisai, the death knell for a trio of obesity drugs that launched early in the last decade. 

Topics

UsernamePublicRestriction

Register

PS003777

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel